What happens when clinical trial results don't align?

Two Phase 3 trials presented at #ESMO2026 did not demonstrate a benefit from adding immunotherapy to chemotherapy MIBC.

Dr. Rob Jones joins Brian and Tom to unpack the findings, explore how they fit alongside the NIAGARA data, and discuss the implications for neoadjuvant and adjuvant treatment strategies.

🎙️ Episode 521 of The Uromigos Podcast is now live: https://bit.ly/4z7YGQ5

#Uromigos #BladderCancer #GUOncology